Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy
Abstract Recent introduction of monoclonal antibodies targeting immune checkpoints to harness antitumor immunity has revolutionized the cancer treatment landscape. The therapeutic success of immune checkpoint blockade (ICB)-based therapies mainly relies on PD-1/PD-L1 and CTLA-4 blockade. However, th...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2023-08-01
|
| Col·lecció: | Molecular Cancer |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s12943-023-01845-4 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|